3rd Aug 2015 07:00
3 August 2015
Further re Directorate Change
Clinigen Group plc (the 'Group', AIM: CLIN) confirms that Martin Abell will join the Group as an executive director and CFO elect with immediate effect.
As announced on 1 April 2015, Robin Sibson, the current CFO, intends to step down and become a non-executive director of the Group. This will happen following a period of handover to Mr Abell after which he will step up as full time CFO.
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Martin James Abell, aged 41 years, is not currently a director of any other companies but has been a director of the following companies during the five years preceding the date of this announcement:
Hays International Holdings Limited
Hays AG
Hays Temp GmbH
Hays (Schweitz) AG
There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
-Ends-
Contact Details
Clinigen Group plc |
Tel: +44 (0) 1283 495010 |
Peter George, Group Chief Executive Officer Shaun Chilton, Group Deputy CEO | |
Robin Sibson, Group Chief Financial Officer | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade/Freddie Barnfield (Nominated Adviser) James Black/Tom Ballard (Corporate Broking) | |
Peel Hunt LLP | Tel: +44 (0) 20 7418 8900 |
James Steel/Jock Maxwell Macdonald | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell/Jayne Crook/Emma Barlow | Email: [email protected] |
Notes to Editors
About Clinigen Group
Clinigen Group is a global pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time. The Group consists of four synergistic businesses that provide medicines to patients with unmet medical need; through Clinigen CTS we manage the supply of commercial medicines for clinical trials, through Idis Managed Access we run early access programs for our own and other companies' portfolios, our Idis Global Access team works directly with healthcare providers to enable ethical compliant access to unlicensed medicines, and through Clinigen SP, we market our own portfolio of niche commercial products.
We are global leaders in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need.
For more information, please visit www.clinigengroup.com.
Related Shares:
CLIN.L